Gamma-aminobutyric acid type A receptor, benzodiazepine site (GABA_A receptor (benzodiazepine site))

The benzodiazepine site of the gamma-aminobutyric acid type A (GABA_A) receptor is a specific modulatory binding site located at the interface between the α and γ subunits of the pentameric GABA_A receptor complex, a ligand-gated chloride ion channel predominantly found in the central nervous system. Benzodiazepines and related drugs bind to this site, acting as positive allosteric modulators to enhance the effect of the inhibitory neurotransmitter GABA, increasing the frequency of chloride channel opening and thereby promoting neuronal hyperpolarization and inhibition[1][2][3][4][5]. This site is the principal molecular target for the benzodiazepine class of anxiolytic, sedative, muscle relaxant, and anticonvulsant drugs. Interaction at the benzodiazepine site is clinically important for the management of various CNS disorders but is associated with notable safety concerns, particularly related to dependence, withdrawal, and CNS depression[1][4][5].

Other names

GABA_A receptor benzodiazepine binding siteBenzodiazepine binding site of GABA_A receptorBZD binding site of GABA_A receptorGABA_A benzodiazepine site

Positive allosteric modulation (benzodiazepine agonists enhance GABAergic signaling by increasing channel opening frequency)[1][2][4][5] - Negative allosteric modulation (inverse agonists diminish GABAergic signaling) - Competitive antagonism at the benzodiazepine site (e.g., flumazenil)[2][4]